Table 1

Clinicopathological characteristics of patients with epithelial ovarian cancer

Characteristicp53 mutation analysisp53 protein expressionp53 alterations
p53 mutationp53 wild-typePaOverexpressionNormal expressionPap53 alterationNormal p53Pa
Patients, n (%)99 (56)79 (44)110 (62)68 (38)132 (74)46 (26)
Median age (yr)57530.041b57520.06b57520.056b
Histological subtype, n (%)
 Serous60 (61)51 (65)0.0867 (61)44 (65)0.6279 (60)32 (70)0.4
 Mucinous2 (2)6 (8)4 (4)4 (6)4 (3)4 (9)
 Endometriod18 (18)12 (15)20 (18)10 (15)24 (18)6 (13)
 Clear cell1 (1)5 (6)2 (2)4 (6)4 (3)2 (4)
 Brenner1 (1)01 (1)01 (1)0
 Undifferentiated8 (8)2 (3)7 (6)3 (4)9 (7)1 (2)
 Mixed epithelial7 (7)3 (4)7 (6)3 (4)9 (7)1 (2)
 Unclassified2 (2)02 (2)02 (2)0
Clinical stage, n (%)
 FIGO I11 (11)25 (32)0.00118 (17)18 (28)0.1121 (16)15 (34)0.005
 FIGO II3 (3)5 (7)4 (4)4 (6)5 (4)2 (7)
 FIGO III67 (70)39 (51)72 (67)34 (52)83 (64)23 (52)
 FIGO IV15 (16)8 (10)14 (13)9 (14)20 (16)3 (7)
Grade of differentiation, n (%)
 I (well)7 (7)21 (27)<0.0018 (7)20 (29)<0.00111 (8)17 (37)<0.001
 II (moderate)25 (25)27 (34)32 (29)20 (29)36 (27)16 (35)
 III (poor)67 (68)31 (39)70 (64)28 (41)85 (64)13 (28)
Residual tumor, n (%)
 No residual tumor32 (39)39 (56)0.0436 (40)35 (56)0.06246 (41)25 (60)0.044
 ≤2 cm29 (35)19 (27)32 (35)16 (26)37 (33)11 (26)
 >2 cm22 (27)12 (17)23 (25)11 (18)28 (25)6 (14)
Lymph nodes, n (%)
 Negative9 (11)15 (22)0.213 (15)11 (17)0.516 (15)8 (19)0.24
 Positive20 (25)17 (25)20 (24)17 (27)24 (23)13 (30)
 Not resected50 (63)37 (54)52 (61)35 (56)65 (62)22 (51)
DNA-ploidy, n (%) (total, 102)
 Diploid21 (39)33 (69)0.00328 (48)26 (59)0.2831 (44)23 (74)0.004
 Aneuploid33 (61)15 (31)30 (52)18 (41)40 (56)8 (26)
S-Phase fraction, n (%) (total, 102)
 Low (<5%)4 (7)22 (46)<0.0016 (10)20 (45)<0.0019 (13)17 (55)<0.001
 Intermediate (5–14.4%)26 (48)21 (44)29 (50)18 (41)35 (49)12 (39)
 High (≥14.5%)24 (44)5 (10)23 (40)6 (14)27 (38)2 (6)
Treatment, n (%)c
 Cisplatin-cyclophosphamide27 (32)27 (39)0.4334 (37)20 (33)0.5539 (35)15 (38)0.98
 Carboplatin-cyclophosphamide13 (16)7 (10)13 (14)7 (12)15 (14)5 (13)
 Other regimens25 (31)16 (23)26 (29)15 (25)31 (28)10 (25)
 No chemotherapy17 (21)19 (28)18 (20)18 (30)26 (23)10 (25)
 No information, n1710198216
  • a χ2 test for two categories, Mantel-Haenszel test for three or more categories.

  • b Wilcoxon test.

  • c Chemotherapy regimens are described in “Materials and Methods.”